# US 2012/0251545 A1 · Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251545 A1
- Document ID: US20120251545A1
- Status: Published application
- Kind: A1
- Application number: 13/271,678
- Filed: 2011-10-12
- Published: 2012-10-04
- Earliest claimed: 2005-04-13
- Assignees: Astex Therapeutics Limited
- Inventors: Gianni Chessari; Miles Stuart Congreve; Martyn Frederickson; Christopher William Murray; Eva Figueron Navarro; Alison Jo-Anne Woolford
- Web page: https://patentgrep.com/patent/US20120251545A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 65/21: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- C07D 215/08: with acylated ring nitrogen atom
- C07D 217/06: with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 491/08: Bridged systems
- C07D 491/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The invention provides a combination comprising an Hsp90 inhibitor compound of the formula (VII): or tautomer or salt thereof and one or more therapeutic agents selected from topoisomerase I inhibitors; antimetabolites; tubulin targeting agents; DNA binder and topoisomerase II inhibitors; alkylating agents; monoclonal antibodies; anti-hormones; signal transduction inhibitors; proteasome inhibitors; DNA methyl transferases; cytokines; retinoids and HDAC or HAT modulators.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A combination comprising:
(i) an Hsp90 inhibitor compound of the formula (VII):
or tautomer thereof;
wherein n is 1, 2 or 3;
R1 and R2a are both hydroxy;
R3 is selected from isopropyl and tert-butyl;
R4a is hydrogen;
R8 is hydrogen;
R10b is selected from a group consisting of halogen, OH, NH2, CH2OH, CH2NH2, O—C1-6-alkyl, NH—C1-6 alkyl, aryl, heteroaryl, C3-7 cycloalkyl, heterocyclyl, O-heteroaryl, O—C3-7 cycloalkyl, O-heterocycloalkyl, C(═O)C1-6 alkyl, C(═O)OC1-6 alkyl, C(═O)NH2, C(═O)NHC1-6 alkyl, C(═O)N(C1-6 alkyl)2, NH(C1-6 alkyl), N(C1-6 alkyl)2, NC(═O)C1-6 alkyl, C6 aryl, OC6 aryl, C(═O)C6aryl, C(═O)OC6aryl, C(═O)NH2, C(═O)NHC6aryl, C(═O)N(C6 aryl)2, NH(C6 aryl), N(C6 aryl)2, NC(═O)C6 aryl, C5-6 heterocyclyl, OC5-6 heterocyclyl, C(═O)C5-6 heterocyclyl, C(═O)OC5-6 heterocyclyl, C(═O)NHC5-6 heterocyclyl, C(═O)N(C5-6 heterocyclyl)2, NH(C5-6 heterocyclyl), N(C5-6 heterocyclyl)2, NC(═O)C5-6 heterocyclyl, C(═O)NHC1-6 alkyl, C5-6 aryl, S(═O)C1-6 alkyl, S(═O)N—C1-6 alkyl and SO2N—C1-6 alkyl; and a group [sol], CH2[sol] or OCH2CH2[sol] where [sol] is selected from the following groups
(ii) one or more therapeutic agents selected from topoisomerase I inhibitors;
antimetabolites; tubulin targeting agents; DNA binder and topoisomerase II inhibitors;
alkylating agents; monoclonal antibodies; anti-hormones; signal transduction inhibitors;
proteasome inhibitors; DNA methyl transferases; cytokines; retinoids and HDAC or HAT modulators.

### Claim 13 (depends on 12)

A combination according to claim 12 wherein R10b is selected from a group R10c consisting of [sol], CH2[sol] or OCH2CH2[sol] where [sol] is selected from the following groups:

### Claim 14 (depends on 12)

A combination according to claim 12 wherein R3 is isopropyl.

### Claim 15 (depends on 12)

A combination according to claim 12 wherein n is 1.

### Claim 16 (depends on 14)

A combination according to claim 14 wherein n is 1.

### Claim 17 (depends on 12)

A combination according to claim 12 wherein the Hsp90 inhibitor compound is selected from:
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-yl)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-hydroxy-1-methyl-piperidin-4-yl)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(1-methyl-piperidin-4-ylamino)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-piperazin-1-yl-1,3-dihydro-isoindol-2-yl)-methanone; and
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-dimethylaminomethyl-1,3-dihydroisoindol-2-yl)-methanone;
and tautomers thereof.

### Claim 18 (depends on 17)

A combination according to claim 17 wherein the Hsp90 inhibitor compound is selected from:
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-hydroxy-1-methyl-piperidin-4-yl)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone; or
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(1-methyl-piperidin-4-ylamino)-1,3-dihydro-isoindol-2-yl]-methanone;
and tautomers thereof.

### Claim 19 (depends on 18)

A combination according to claim 18 wherein the Hsp90 inhibitor compound is:
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone;
and tautomers thereof.

### Claim 20 (depends on 12)

A combination according to claim 12 wherein the Hsp90 inhibitor compound is in the form of a salt.

### Claim 21 (depends on 17)

A combination according to claim 17 wherein the Hsp90 inhibitor compound is in the form of a salt.

### Claim 22 (depends on 18)

A combination according to claim 18 wherein the Hsp90 inhibitor compound is in the form of a salt.

### Claim 23 (depends on 19)

A combination according to claim 19 wherein the Hsp90 inhibitor compound is in the form of a salt.

### Claim 24 (depends on 12)

A combination according to claim 12 wherein the one or more therapeutic agents are selected from antimetabolites; tubulin targeting agents; alkylating agents; anti-hormones; signal transduction inhibitors and proteasome inhibitors.

### Claim 25 (depends on 17)

A combination according to claim 17 wherein the one or more therapeutic agents are selected from antimetabolites; tubulin targeting agents; alkylating agents; anti-hormones; signal transduction inhibitors and proteasome inhibitors.

### Claim 26 (depends on 19)

A combination according to claim 19 wherein the one or more therapeutic agents are selected from antimetabolites; tubulin targeting agents; alkylating agents; anti-hormones; signal transduction inhibitors and proteasome inhibitors.

### Claim 27 (depends on 12)

A combination according to claim 12 wherein the one or more therapeutic agents comprises an antimetabolite.

### Claim 28 (depends on 12)

A combination according to claim 12 wherein the one or more therapeutic agents comprises a tubulin targeting agent.

### Claim 29 (depends on 12)

A combination according to claim 12 wherein the one or more therapeutic agents comprises an alkylating agent.

### Claim 30 (depends on 12)

A combination according to claim 12 wherein the one or more therapeutic agents comprises an anti-hormone.

### Claim 31 (depends on 12)

A combination according to claim 12 wherein the one or more therapeutic agents comprises a signal transduction inhibitor.

### Claim 32 (depends on 12)

A combination according to claim 12 wherein the one or more therapeutic agents comprises a proteasome inhibitor.
